40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
